Carl Ernst obtains 1.6 million Euros to support research on Schinzel-Giedion Syndrome

Congratulations to Dr. Carl Ernst and his European collaborators on obtaining a grant from the European Joint Programme for Rare Diseases, for their project, Development and preclinical testing in human cell models and transgenic mice of a novel treatment for Schinzel-Giedion Syndrome. The funding, which totals 1.6 million Euros, will support an international research collaboration dedicated to Schinzel-Giedion Syndrome (SGS), an ultra-rare genetic disease. This is the first time a major funding initiative has been dedicated to the disease.

“We could not be happier to partner and collaborate with families affected by SGS to advance treatments for this disease,” said Ernst, who coordinated the application. “With this EU support, our international group of experts has the opportunity to drive science forward and hopefully reduce suffering in children with this neglected rare disease.”


See the McGill Research & Innovation article for more details.